About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer

by Medindia Content Team on August 26, 2007 at 3:17 PM
Font : A-A+

Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

NSCLC is the most common form of lung cancer, a difficult to treat disease that kills over 3,000 people per day worldwide.(1) NSCLC is usually diagnosed at an advanced stage, meaning individuals diagnosed with the disease typically have a life expectancy of only 8 to 10 months.(2),(3) Avastin is the only first-line therapy to demonstrate improved survival benefits beyond one year in patients with advanced NSCLC.

Advertisement

The approval is based on data from the pivotal US phase III trial (E4599) and the 'Avastin in Lung' (AVAiL) phase III trial. Both studies demonstrate that Avastin is effective for the treatment of patients with NSCLC in combination with platinum-based chemotherapy. The approval is for the use of Avastin at a dose of 7.5 or 15 mg/kg, in combination with platinum-based chemotherapy, for the first-line treatment of patients with unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology. The broad label that Avastin has received for the treatment of NSCLC allows the combination of Avastin with any platinum-based chemotherapy regimens (for example, together with taxanes or gemcitabine) at the choice of the physician.

Professor Christian Manegold, Professor of Medicine at Heidelberg University, University Medical Center Mannheim, Germany and Principal Investigator of the AVAiL trial, was enthusiastic about the news: "Lung cancer is an extremely difficult disease to treat and Avastin has proven that it can prolong the life of patients with NSCLC. A treatment like Avastin that breaks through the one year survival barrier is a big step forward. The European approval for Avastin means we can reassess our expectations for lung cancer patient survival."

Avastin is the first and only anti-angiogenic agent which has been shown to consistently deliver improved overall and/or progression-free survival for patients with colorectal, lung, breast and kidney cancer.

Source: PRNewswire
SRM/B
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
Toothache
World AIDS Day 2021 - End Inequalities, End AIDS
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Lung Cancer Cancer and Homeopathy Cancer Facts Asbestosis Cancer Pneumoconiosis Silicosis 

Recommended Reading
Untreatable Eye Disease Improves With Avastin
Patients with radiation retinopathy who were destined to go blind within five years now can keep ......
Asbestosis
Asbestosis is a chronic inflammatory lung disease that occurs due to long term exposure to asbestos ...
Lung Cancer
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with ...
Pneumoconiosis
Pneumoconiosis is a group of lung diseases caused by inhaled dust particles. It causes inflammation ...
Silicosis
Silicosis is a lung disease caused by inhalation of crystalline free silica dust. It is characterise...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use